VISCHER advises Mossana with Seed Financing Round extension

Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital, a US based venture capital fund specializing in sleep, and the German investment firm High-Tech Gründerfonds (HTGF). Both investors joins lead founding investor Forty51 Ventures to complete the Seed stage investment syndicate.

Founded in 2022, the company will utilize the funds for manufacturing and regulatory activities in preparation for a multi-study clinical development program.

The VISCHER team includes partner Matthias Staehelin (pictured) and associates Timothy Woodtli and Christoph Enz, all corporate/m&a.